Macular degeneration trials in Czechia

In Czechia 12 Also abroad 220

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Where
Prague
Age
50 years and over
People
272 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00
Phase 3Taking people
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Where
Mladá Boleslav, Ostrava, Prague, Prague 6
Age
50 years and over
People
250 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00
Phase 2/3Taking people
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Where
Prague, Prague 5
Age
60 years and over
People
274 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00
Phase 3Taking people
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Where
Ostrava, Prague, Prague 6
Age
50 years and over
People
561 worldwide
Run by
AbbVie
See details and how to joinNCT07007065 · EU 2024-512298-28-00
Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Where
Mladá Boleslav, Náchod, Ostrava, Pardubice V, Plzen 23, Prague, Prague 5
Age
50 years and over
People
304 worldwide
Run by
Amgen
See details and how to joinNCT07614776 · EU 2025-523500-72-00
Phase 2/3Not yet taking people in Czechia
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
Where
Ostrava, Pardubice V, Prague, Prague 5
Age
65 years and over
People
125 worldwide
Run by
Shenzhen Oculgen Biomedical Technology Co. Ltd.
See details and how to join2026-526648-11-00 · EU 2026-526648-11-00
Phase 2Taking people
A Study in Adults With Geographic Atrophy
Where
Pardubice V, Prague, Prague 5
Age
60 years and over
People
300 worldwide
Run by
Sitala Bio LTD
See details and how to joinNCT07606365 · EU 2026-525738-40-00
Phase 2/3Taking people
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
Where
Mladá Boleslav, Náchod, Ostrava, Prague, Prague 5
Age
18 years and over
People
250 worldwide
Run by
Eyebiotech Limited
See details and how to join2025-524894-17-00 · EU 2025-524894-17-00
Phase 2Taking people
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Where
Náchod, Prague, Prague 5, Sokolov
Age
55 years and over
People
324 worldwide
Run by
ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00
Phase 2Taking people
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Where
Prague, Praha Klanovice
Age
60 years and over
People
240 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Where
Mladá Boleslav, Náchod, Prague
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07496567
Phase 4Taking people
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Where
Prague
People
100
Run by
Faculty Hospital Kralovske Vinohrady
See details and how to joinNCT06875245